Alex Thompson CFA
Stock Analyst at Stifel Nicolaus
(4.92)
# 191
Out of 4,408 analysts
259
Total ratings
64.6%
Success rate
37.6%
Average return
Main Sectors:
Stocks Rated by Alex Thompson CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics | Maintained: Buy | $28 | $13.61 | +105.73% | 6 | Jun 8, 2026 | |
| ARGX argenx SE | Rated: Buy | $1,222 → $1,255 | $884.20 | +41.94% | 28 | May 29, 2026 | |
| EQ Equillium | Reiterated: Buy | $5 | $2.80 | +78.57% | 2 | May 28, 2026 | |
| IMVT Immunovant | Maintained: Buy | $49 | $33.44 | +46.53% | 16 | May 25, 2026 | |
| AVTX Avalo Therapeutics | Maintained: Buy | $36 → $39 | $14.60 | +167.12% | 6 | May 15, 2026 | |
| VRDN Viridian Therapeutics | Maintained: Buy | $48 → $39 | $16.30 | +139.26% | 17 | May 13, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $107 | $83.58 | +28.02% | 17 | May 12, 2026 | |
| ASND Ascendis Pharma | Maintained: Buy | $332 → $328 | $223.29 | +46.89% | 16 | May 8, 2026 | |
| ACRS Aclaris Therapeutics | Maintained: Hold | $2 → $4 | $4.36 | -8.26% | 13 | May 8, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintained: Buy | $83 | $35.07 | +136.69% | 11 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $16.10 | +148.45% | 2 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $43 | $53.80 | -20.07% | 29 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $43 | $36.03 | +19.34% | 1 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $54 | $20.84 | +159.12% | 1 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $72 → $150 | $68.90 | +117.71% | 9 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $1.69 | +195.86% | 3 | Apr 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $44 | $23.00 | +91.30% | 4 | Apr 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $86.06 | - | 13 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $65 → $120 | $82.47 | +45.51% | 11 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 → $85 | $59.51 | +42.83% | 11 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $13 → $19 | $19.19 | -0.99% | 8 | Mar 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $58 → $68 | $32.12 | +111.71% | 6 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $68 → $114 | $85.61 | +33.16% | 9 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $3 | $1.14 | n/a | 17 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $15.07 | n/a | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $34 | $40.04 | n/a | 1 | Aug 8, 2023 |
Cullinan Therapeutics
Jun 8, 2026
Maintained: Buy
Price Target: $28
Current: $13.61
Upside: +105.73%
argenx SE
May 29, 2026
Rated: Buy
Price Target: $1,222 → $1,255
Current: $884.20
Upside: +41.94%
Equillium
May 28, 2026
Reiterated: Buy
Price Target: $5
Current: $2.80
Upside: +78.57%
Immunovant
May 25, 2026
Maintained: Buy
Price Target: $49
Current: $33.44
Upside: +46.53%
Avalo Therapeutics
May 15, 2026
Maintained: Buy
Price Target: $36 → $39
Current: $14.60
Upside: +167.12%
Viridian Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $48 → $39
Current: $16.30
Upside: +139.26%
Spyre Therapeutics
May 12, 2026
Maintained: Buy
Price Target: $107
Current: $83.58
Upside: +28.02%
Ascendis Pharma
May 8, 2026
Maintained: Buy
Price Target: $332 → $328
Current: $223.29
Upside: +46.89%
Aclaris Therapeutics
May 8, 2026
Maintained: Hold
Price Target: $2 → $4
Current: $4.36
Upside: -8.26%
Crinetics Pharmaceuticals
May 8, 2026
Maintained: Buy
Price Target: $83
Current: $35.07
Upside: +136.69%
May 7, 2026
Maintained: Buy
Price Target: $40
Current: $16.10
Upside: +148.45%
May 5, 2026
Maintained: Hold
Price Target: $43
Current: $53.80
Upside: -20.07%
May 1, 2026
Initiated Coverage: Buy
Price Target: $43
Current: $36.03
Upside: +19.34%
May 1, 2026
Initiated Coverage: Buy
Price Target: $54
Current: $20.84
Upside: +159.12%
Apr 28, 2026
Maintained: Buy
Price Target: $72 → $150
Current: $68.90
Upside: +117.71%
Apr 4, 2026
Maintained: Buy
Price Target: $5
Current: $1.69
Upside: +195.86%
Apr 4, 2026
Maintained: Buy
Price Target: $44
Current: $23.00
Upside: +91.30%
Mar 23, 2026
Maintained: Buy
Price Target: n/a
Current: $86.06
Upside: -
Mar 10, 2026
Maintained: Buy
Price Target: $65 → $120
Current: $82.47
Upside: +45.51%
Mar 5, 2026
Maintained: Buy
Price Target: $56 → $85
Current: $59.51
Upside: +42.83%
Mar 1, 2026
Maintained: Hold
Price Target: $13 → $19
Current: $19.19
Upside: -0.99%
Feb 26, 2026
Maintained: Buy
Price Target: $58 → $68
Current: $32.12
Upside: +111.71%
Dec 15, 2025
Maintained: Buy
Price Target: $68 → $114
Current: $85.61
Upside: +33.16%
Mar 3, 2025
Downgraded: Hold
Price Target: $32 → $3
Current: $1.14
Upside: n/a
Nov 7, 2024
Reiterated: Buy
Price Target: $23
Current: $15.07
Upside: n/a
Aug 8, 2023
Initiated Coverage: Buy
Price Target: $34
Current: $40.04
Upside: n/a